Purple Biotech annual stock-based compensation
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Purple Biotech Stock-Based Compensation Growth & History (PPBT)
Purple Biotech's stock-based compensation was $309,000 for fiscal 2025.
View full Purple Biotech company overviewPurple Biotech annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $309,000 | −$273,000 | −46.91% |
| 2024 | 2024-12-31 | $582,000 | −$1.3M | −68.96% |
| 2023 | 2023-12-31 | $1.9M | −$537,000 | −22.26% |
| 2022 | 2022-12-31 | $2.4M | $330,000 | +15.85% |
| 2021 | 2021-12-31 | $2.1M | −$563,000 | −21.29% |
| 2020 | 2020-12-31 | $2.6M | $1.4M | +107.78% |
| 2019 | 2019-12-31 | $1.3M | $500,000 | +64.68% |
| 2018 | 2018-12-31 | $773,000 | −$1.5M | −66.51% |
| 2017 | 2017-12-31 | $2.3M | $1.9M | +477.00% |
| 2016 | 2016-12-31 | $400,000 | $341,000 | +577.97% |
| 2015 | 2015-12-31 | $59,000 | — | — |
Purple Biotech quarterly stock-based compensation
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $67,000 | $8,000 | +13.56% |
| Q1 2026 | 2026-03-31 | $93,000 | — | — |
| Q4 2025 | 2025-12-31 | −$43,000 | — | — |
| Q3 2025 | 2025-09-30 | $200,000 | — | — |
| Q2 2025 | 2025-06-30 | $59,000 | — | — |
Purple Biotech stock-based compensation trends
Over the last five fiscal years, Purple Biotech's stock-based compensation decreased from $2.6M to $309,000, a change of −$2.3M. The latest reported quarter, Q2 2026, shows $67,000.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Purple Biotech source filings ↗